Olivia Monica Sigovan1, Amine Bessaad1, Elena Kaye2, Eric Lancelot3, Claire Corot3, Nicolas Provost4, Zouher Majd4, Magali Breisse4, Emmanuelle Canet-Soulas1
1CREATIS-LRMN Laboratory, Lyon1 University, Lyon, France; 2Radiology, Stanford University, United States; 3Guerbet Group, Paris, France; 4Genfit, Lille, France
Irbesartan (SR 47436) is an orally active nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. We report here an USPIO-enhanced MRI follow-up study performed on apolipoprotein (apo) E-deficient mice with the goal of following Irbesartans therapeutic effect on the development and progression of atherosclerotic lesions. Irbesartan lead to a marked reduction in the plaque formation. Post USPIO T2* values measured in the vessel wall showed significant decrease compared to baseline values, however no differences were found between treated and not treated groups. The obtained information (from the ascending aorta) may not be representative of the general effect of the drug.